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Abstract
Background: Mental health inpatients smoke at higher rates than the general population and are
disproportionately affected by tobacco dependence. Despite the advent of smoke free policies within mental
health hospitals, limited systems are in place to support a cessation attempt post hospitalisation, and international
evidence suggests that most smokers return to pre-admission smoking levels following discharge. This protocol
describes a randomised controlled trial that will test the feasibility, acceptability and efficacy of linking inpatient
smoking care with ongoing community cessation support for smokers with a mental illness.
Methods/Design: This study will be conducted as a randomised controlled trial. 200 smokers with an acute
mental illness will be recruited from a large inpatient mental health facility. Participants will complete a baseline
survey and will be randomised to either a multimodal smoking cessation intervention or provided with hospital
smoking care only. Randomisation will be stratified by diagnosis (psychotic, non-psychotic). Intervention
participants will be provided with a brief motivational interview in the inpatient setting and options of ongoing
smoking cessation support post discharge: nicotine replacement therapy (NRT); referral to Quitline; smoking
cessation groups; and fortnightly telephone support. Outcome data, including cigarettes smoked per day, quit
attempts, and self-reported 7-day point prevalence abstinence (validated by exhaled carbon monoxide), will be
collected via blind interview at one week, two months, four months and six months post discharge. Process
information will also be collected, including the use of cessation supports and cost of the intervention.
Discussion: This study will provide comprehensive data on the potential of an integrated, multimodal smoking
cessation intervention for persons with an acute mental illness, linking inpatient with community cessation support.
Trial Registration: Australian and New Zealand Clinical Trials Registry ANZTCN: ACTRN12609000465257
Background
Persons with a mental illness are one of the largest
remaining groups of smokers, comprising an estimated
32% of the total smokers in Australia [1]. Consistently
high rates of smoking have been found among the men-
tally ill in Australia and internationally, ranging from
36% in community samples to above 90% among inpati-
ents with psychosis [2-5]. Smokers with a mental illness
are also more nicotine dependent [6], more likely to
smoke unfiltered cigarettes [7] and less likely to quit
than smokers in the general population [8-10]. Conse-
quently, smokers with a mental illness have a signifi-
cantly reduced life expectancy and are more likely to die
from smoking related disease including cancers, cardio-
vascular disease, respiratory disease and stroke [11,12].
Evidence for the effectiveness of multimodal smoking
cessation interventions utilising combined pharmacolo-
gical and psychosocial support is well established for
smokers in the general population [13-15]. Recent evi-
dence suggests that smokers with a mental illness have
similar levels of motivation to quit as the general popu-
lation [16-18] and smoking cessation intervention strate-
gies can be equally effective among this group [19-21].
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found to be effective among US veterans with Post-
Traumatic Stress Disorder (PTSD) [22], depressed smo-
kers [23], and in smokers with schizophrenia [24].
General hospitals can provide a base for the initiation
of effective smoking cessation interventions [25-28].
Abstaining from tobacco during hospitalisation has been
associated with higher abstinence rates at 6 months post
discharge [29]. The recent introduction of smoke-free
policies in Australian mental health facilities [30] pro-
vides the opportunity for smokers to temporarily abstain
from cigarettes in a supportive environment, and may
facilitate sustained cessation attempts upon discharge
[2,31]. Hospitalisation within a smoke free mental health
facility has been found to increase patients’ desire to
quit smoking during admission [4,31], and has been
associated with a reduction in daily cigarette consump-
tion from admission to discharge [2].
However, the limited data available indicate that
smoke-free policies in mental health facilities appear
to have had little effect on long term cessation [25], a
finding suggested to be due in part to the lack of
coordination between inpatient and community smok-
ing cessation treatment [32,33]. Systematic reviews
show that by better integrating inpatient smoking care
with post discharge cessation support, long term quit
rates are increased among general hospital patients
[27,28]. However, in the context of mental health ser-
vices, low levels of smoking cessation treatment have
been found in both inpatient and community-based
psychiatric services [34-36], and as a consequence,
many smokers return to pre admission smoking levels
upon discharge from a mental health hospital
[4,31,37]. The limited provision of smoking cessation
treatment in community-based psychiatric services, to
which many patients are likely to be referred upon
discharge, highlights the need for integrated post-dis-
charge smoking cessation treatment for smokers with
a mental illness [32,33].
Although an Australian randomised control trial of
outpatients with psychosis reported that a multimodal
smoking cessation intervention was effective in reducing
smoking rates [21], the authors are not aware of any
published studies that have examined the effectiveness
of integrating inpatient smoking cessation care with
community cessation support for individuals with a
mental illness. This study is the first of its kind interna-
tionally to test, via randomised controlled trial, the feasi-
bility, acceptability and efficacy of integrating inpatient
smoking care with post discharge ongoing, multimodal
smoking cessation treatment for persons with an acute
mental illness. This paper describes the methodology to
be employed in the conduct of this trial.
Methods/Design
Study aim
The aim of this study is to test a multimodal smoking
cessation intervention, linking hospital inpatient care (in
a smoke free mental health facility) with post-discharge
community cessation support for smokers with a mental
illness. This study aims to evaluate the feasibility,
acceptability and efficacy of the integrated intervention
to reduce smoking behaviour and encourage quitting
post-discharge. This study will also provide a detailed
evaluation of the uptake and use of the study interven-
tion components, including the cost of the intervention.
Study Design and Setting
This study will employ a single-site prospective rando-
mised controlled study design, and will be reported in
accordance with the requirements of the CONSORT
statement [38]. It will be conducted at a large regional
inpatient mental health facility located in the Hunter
New England region of New South Wales (NSW), Aus-
tralia. Inpatients will be recruited from three units
within the facility (two general adult units and one dual
diagnosis unit), with a total of 66 beds, with three other
units excluded from this study (two emergency psychia-
tric care units and one geriatric unit). The majority of
the study intervention will be delivered in the commu-
nity setting, upon participants’ discharge from hospital
and contact between participants and project officers
will occur via telephone and mail.
Figure 1 shows the study design. Mental health inpati-
ents who report being current smokers will be
approached to participate. Participants will be randomly
allocated to intervention or control conditions. A per-
muted block randomisation approach will be used so
that the distribution of participants by diagnosis (psy-
chotic; non-psychotic) across treatment conditions will
be maintained regardless of the final sample size [39,40].
Inpatients allocated to the intervention condition will
receive a brief motivational intervention from the
research staff, and will be offered a range of psychoso-
cial and/or pharmacological supports for up to 16 weeks
post discharge. An initial two week supply of nicotine
replacement therapy (NRT) is provided at discharge,
and details of the patient’s participation in the study will
be added to their electronic discharge summary, for the
information of health professionals providing post-dis-
charge treatment.
Patients allocated to the control condition will receive
standard hospital smoking care only, which may include
provision of up to 3 days free NRT and a referral to
Quitline upon discharge. Baseline data will be collected
during the initial face to face interview in the inpatient
setting by trained project officers.
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interviewers independent of the study, via telephone
interview at four time points following discharge: one
week, two months, four months and six months.
This project has received ethics approval from the
Hunter New England Human Research Ethics Commit-
tee, HREC reference no: 08/04/16/5.10, and the
University of Newcastle Human Research Ethics Com-
mittee reference no: H-2008-0191.
Participants and research eligibility
Approximately 200 smokers will be recruited to the
study (100 in each condition). Written, informed con-
sent will be obtained from each potential participant
before commencement of the baseline interview.
1 week
2 months
4 months
6 months
o 2-3 day and 1 week post discharge
support call
Plus, ‘additional’ intervention: 
o Up to 12 weeks NRT
o Community smoking cessation 
support group
o Proactive Quitline referral
o Up to 16 weeks fortnightly 
telephone support 
Hospital smoking care, plus:
o Initial 2 week NRT supply
o Participant project details on 
discharge summary
Inpatient setting
On discharge
Community setting
Follow-up interviews
Hospital smoking care only:
o 3 days free NRT on discharge
o Proactive Quitline referral
Recruit participants as mental 
health inpatients
Intervention Control
Baseline interview
Random allocation
Hospital smoking care only Hospital smoking care, plus: 
‘Base’ intervention:
o Brief motivational interview
o Self-help material
Figure 1 Study Design.
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Participants will be required to be at least 18 years of
age and to self report being a current or occasional
smoker upon admission to hospital. Participants will
also be required to have a contact telephone number
and address at the time of recruitment, and be judged
by clinical staff to be physically and psychologically cap-
able to complete the face to face baseline interview. Any
person who presents severe psychological distress during
the baseline interview will be referred to clinical staff
and the interview will cease. Eligibility will be reassessed
after these patients have stabilised.
Exclusion criteria
Patients will be excluded if they are not current smo-
kers, are younger than 18 years of age, do not have a
current contact telephone number or address, are non
English speaking, or if their current physical or mental
wellbeing is judged by clinical staff to be too unstable to
participate.
Recruitment and Allocation
Recruitment of participants will be ongoing over,
approximately, a one year period. A systematic daily
(weekdays only) review of current patients within each
unit will be undertaken in conjunction with clinical
staff, with advice provided to project staff regarding
those patients deemed to be sufficiently stable to be
approached on that day. The study will aim to approach
all patients at some time during their stay, establishing
the smoking status of those patients who agree to speak
with project staff. If patients report being a non or ex-
smoker, they will be thanked for their time, and the
interview will cease. Eligible patients will be offered par-
ticipation in the project, provided with the information
statement about the research, and written informed con-
sent will be obtained. Participants will complete a base-
line interview with the project officer (up to 1 hour
duration).
Allocation
Prior to commencement of recruitment, a random allo-
cation sequence will be generated using SPSS through
consultation with an independent statistician not
actively involved in the project. The randomisation will
follow a permuted block design, restricted to blocks of
10, and stratified by diagnosis (psychotic; non-psychotic)
to ensure an even distribution of participants within and
between treatment conditions [39,40]. The random allo-
cation sequence will be stored with a research assistant
independent of the recruitment process, and all project
officers involved in recruitment and follow-up data col-
lection will be kept blind to the sequence. According to
the order of the random allocation sequence, the
research assistant will place small cards indicating the
treatment condition ("Intervention” or “Control”)i n s i d e
sealed, security envelopes, displaying the sequentially
ordered participant identification code on the exterior.
Following completion of the baseline interview, the pro-
ject officer will provide the participant with the subse-
quent envelope in sequence, and the envelope will be
opened by the participant at the conclusion of the base-
line interview.
Intervention condition
In addition to hospital smoking care, the participants
randomised to the intervention condition will be pro-
vided with a ‘base’ intervention component, comprising
a brief motivational interview and smoking cessation
self-help material in the inpatient setting. Participants
will also be offered the following ‘additional’ compo-
nents of the intervention, to occur post discharge: up to
12 weeks of ongoing NRT; a proactive Quitline referral;
and a referral to community smoking cessation support
groups. Upon discharge, participants will receive an
initial two week supply of NRT, and their participation
in the study will be recorded on the hospital discharge
summary and sent to relevant treating practitioners in
the community. Participants will additionally receive
supportive phone contact at three days, and one week
post hospitalisation, and the delivery of the elected
intervention components will commence. Subsequently,
participants electing any of the ‘additional’ intervention
components will concurrently receive up to 16 weeks of
further fortnightly telephone support.
Intervention content
The smoking cessation intervention focuses on the
adoption of multiple, evidence based cessation strategies
to assist with smoking reduction and abstinence, at the
participant’s discretion [14,15]. Quitting smoking will be
the focus of the intervention. However, a harm minimi-
sation approach will also be employed, through encoura-
ging a reduction in the number of cigarettes smoked per
day [41-44]. At the completion of the baseline interview,
and following allocation to the intervention condition,
participants will receive:
’Base’ Intervention component
a) Smoking cessation self-help material Participants
will be provided with a clear, plastic folder containing a
pamphlet and workbook targeted at smokers with a
mental illness developed by a state government pro-
vided, proactive telephone smoking cessation support
service ‘Quitline’ [45,46], a smoking and mental health
factsheet developed by a national mental health charity
organisation ‘SANE’ [47], and a one page document
(developed by the research team) with instructions on
how to effectively use NRT, and how to manage nico-
tine withdrawals and NRT side effects [48].
b) Brief motivational interview The project officer will
conduct a brief (5-10 minutes) motivational interview by
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designed to motivate the participant towards positive
health behaviour change, including: positives and nega-
tives of smoking and quitting, importance and confi-
dence in quitting, and health and financial costs of
smoking [49].
Immediately upon discharge from hospital, interven-
tion participants will receive:
c) Initial NRT supply To allow for continuation of
inpatient and community smoking cessation treatment,
an initial two week supply of NRT will be provided to
the patient at discharge. Subsequent NRT supplies are
delivered in the community setting (below).
d) Study participation recorded on discharge sum-
mary The project officer will provide brief information
regarding the participants’ engagement in the trial into
t h ea r e ah e a l t hs e r v i c e ’s online discharge summary sys-
tem. This information will be communicated to GPs
and other relevant health professionals upon the partici-
pant’s discharge from hospital, in order for these ser-
vices to support the participants’ ongoing care, and for
this study, their quit attempt in the community setting
[27,28].
Additionally, participants allocated to the intervention
condition will be offered the following supports to com-
mence upon discharge:
’Additional’ intervention component
e) NRT Participants will be offered up to 12 weeks free
NRT [50-52]. An NRT protocol for this trial will be
developed based on a combination NRT algorithm [53],
the area health services’ NRT protocol [30] and the pro-
duct disclosure information for the NRT provided in
this trial. Patch (21, 14 and 7 mg), lozenge, gum (2 and
4 mg), and inhaler (10 mg) will be prescribed according
to the study NRT protocol, and based on a nicotine
dependence assessment [54] and patient preferences.
Combination therapy (patch plus adjunctive) will be
recommended for all smokers. For those who smoke >
20 cigarettes per day, 2 mg gum or lozenge, or 10 mg
inhaler will be offered to manage acute craving. Taper-
ing of NRT dose will not be explicitly advised, but
dosage and frequency of use will be closely reviewed
during fortnightly telephone support.
On the day of recruitment, a project officer will send
an email notification of the NRT prescription to the
participant’s Chief and Junior Medical Officer should
there be any unknown medical concern. An initial 2
week supply of NRT will be provided to the patient at
discharge. Subsequent supplies of NRT will be mailed
fortnightly at the completion of the fortnightly tele-
phone support call (below), in which daily cigarette con-
sumption, nicotine withdrawal symptoms and patient
preferences will be reviewed.
f) Community smoking cessation support groups
Referral will be offered to smoking cessation support
groups developed in conjunction with allied health staff
in local community mental health services, and delivered
by staff in those services [55]. A project officer will com-
plete a referral form for the participant and email it to
the appropriate community mental health service (based
on local government area) upon the participant’sd i s -
charge from hospital. Group facilitators will contact par-
ticipants to complete an initial screening interview and
provide details of the group program. Groups will run
on a rotating basis of one, one hour group for four
weeks, and will follow an informational, group-oriented
support and skills training format, with no specific psy-
chological or behavioural intervention [56,57]. Content
will be tailored to smoking and mental illness, with
topics covered including: understanding nicotine addic-
tion and withdrawal, smoking habits and triggers, bene-
fits of quitting, effective use of NRT, illness
management and interaction with medications, and quit
strategies.
g) Proactive Quitline referral The NSW Quitline
(funded by the Cancer Institute, NSW) [45] is a confi-
dential telephone based service designed to help smo-
kers to reduce or quit tobacco smoking. With the
consent of participants, the project officer will complete
a proactive NSW Quitline referral form at the comple-
tion of the baseline interview, and fax to Quit NSW
upon the participant’s discharge from hospital. The
Quitline will call the participant according to the time
and day suggested by the participant on the form, within
one week of referral. The telephone service typically
involves 6 calls, and a follow-up call conducted three
months following the participants’ elected quit date,
with content including: nicotine dependence; quit strate-
gies; relapse prevention; and information on cessation
products and services [45].
h) Fortnightly telephone support For all intervention
participants, support calls will be conducted by a tele-
phone counsellor at three days, and one week post dis-
charge [58]. If participants elect any of the ‘additional’
intervention supports, these calls will continue fort-
nightly for as long as the participant is engaged with the
intervention (up to 16 weeks total). Each call will follow
a predefined script as developed by the research team.
Topics covered include: uptake, usage, problems and
effectiveness of intervention supports (NRT, Quitline,
community smoking cessation support groups), fort-
nightly review of NRT dosage, assistance with NRT use,
monitoring and managing nicotine withdrawal symp-
toms, daily cigarette consumption, techniques to
improve smoking outcomes, and general psychological
support and encouragement. If participants are receiving
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act as a means for project officers to monitor NRT use,
dosage and side effects, andt os u b s e q u e n t l ym a i la n
appropriate fortnightly supply of NRT.
Intervention personnel, recruitment and training
Recruitment will be conducted by a registered Health
Psychologist and several project officers with four year
undergraduate Psychology degrees. Prior to com-
mencement of recruitment, all recruitment staff will
complete the area health services’ mandatory 2-day
mental health training, concerned with ensuring occu-
pational health and safety when working in the hospi-
tal environment. All recruitment staff will be trained
by a senior member of the research team and psychol-
ogist undertaking recruitment in conducting the base-
line interviews and brief motivational interviewing,
including the conduct of mock interviews, and sitting
in on patient interviews.
The fortnightly telephone support service will be pro-
vided by a registered nurse (and undergraduate psychol-
ogy student), experienced with patient contact and
managing patient issues. The interviewer will undergo
project specific training and will assist in the develop-
ment of the support protocols and content.
Outcome data will be collected by blind telephone
interviewers, independent of the study, with several
years experience in conducting health related telephone
based surveys, but no formal qualifications in psychol-
ogy or social sciences. Interviewers will undergo project
specific training where they will be briefed on the aims
and methodology of the study. Details regarding project
specific issues (including NRT and psychiatric medica-
tion) will be provided to ensure interviewers are able to
prompt participants if they have any difficulty or confu-
sion regarding outcome questions.
Treatment monitoring and fidelity
To ensure integrity of the intervention, members of
the research team will have weekly contact with pro-
ject officers, support call staff and follow-up telephone
interviewers to ensure common issues or concerns are
dealt with in a consistent and timely manner. The
research team will also meet fortnightly with a working
group comprising experienced mental health and drug
and alcohol clinicians employed at the hospital site to
raise and address any issues arising from working
within the hospital and to discuss and gain insight into
the best management of participants throughout the
trial period. The research team will also meet quarterly
with a larger advisory group to discuss the aims of the
trial, ensure recruitment, follow-up and intervention
delivery are occurring to the best standard possible,
and to keep abreast of approach, consent and follow-
up rates.
Control condition
Participants allocated to the control condition will
receive standard hospital nicotine dependence treatment
only. This may include provision of NRT during hospi-
talisation and, upon discharge, up to 3 days provision of
NRT and referral to ‘Quitline’. Nicotine dependence
treatment is known to be limited and to vary in this set-
ting [36].
Data collection and measures
Baseline
T h eb a s e l i n es u r v e yw i l lb ea d m i n i s t e r e da saf a c et o
face interview by project officers, within the inpatient
setting prior to the allocation of treatment condition,
and will be of up to 1 hour duration for both groups.
Contact information
During the baseline interview, contact details will be
obtained directly from the participant, including: home
address, contact phone number, living situation, and
smoking status of housemates. In order to reduce attri-
tion, participants will also be asked to elect and provide
contact details of two ‘contact persons’ (friends or family
members) and for their regular GP or health practi-
tioner (name, phone number and service address) for
use by the research team in the event that participants
can no longer be contacted and new details need to be
obtained [59,60]. Consent will also be gained from the
participant for their contact details to be obtained from
another Hunter New England Area Health Service pro-
viding care, in the event that their contact details
change and the research team cannot contact them
through other means.
Follow-up data collection
Follow-up data will be collected for both groups via
blind telephone interview at one week, two months, four
months and six months post discharge. To enable sub-
sequent assessment of the effectiveness of the blinding,
interviewers will be asked at the completion of the inter-
view to indicate the treatment condition to which they
believe the participant was allocated. If any participant
experiences an acute phase of their psychiatric disorder
during any of the follow-up phone interviews, they will
be encouraged to contact their GP, psychologist or com-
munity mental health team. Participation will continue
as normal unless the participant expresses severe psy-
chological distress and/or they no longer wish to partici-
pate in the trial. To minimise attrition, notices will be
mailed, one week prior the due date, to remind partici-
pants of each upcoming follow-up call [61]. The proto-
col for follow-up calls will comprise up to four weeks of
call attempts, with at least 10 attempts made within the
first seven days of the due date, and regular attempts
thereafter. At the completion of the six month follow-
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fying them that their participation is complete and
thanking them for their contribution to the study.
Demographic information
Demographic details including level of education,
employment status and whether the participant receives
a government support pension will be collected during
the baseline interview. At the completion of the baseline
interview, additional demographic information will be
obtained from the participant’s medical record, by a
Health Psychologist employed by the service, including
participant’s full name, medical record number, age,
address at time of admission, gender, pregnancy status
(if NRT is to be prescribed), marital status, Aboriginal
or Torres Strait Islander cultural identification, date and
length of current admission, smoking status on admis-
sion, nicotine dependence treatment provided during
admission, primary and secondary mental health diag-
noses, medications for mental and general health condi-
tions, and date of most recent previous admission to the
facility (if applicable).
Primary outcome measures
The primary outcomes of this trial relate to changes in
participants’ smoking behaviour. Smoking behaviour will
be assessed at each of the four follow-up surveys (one
week, two, four and six months) by: daily cigarette con-
sumption; number and duration of quit attempts; and
self-reported abstinence. Daily cigarette consumption
and quit attempts are recognised and recommended
outcome measures which are frequently used in this
population [62,63]. When abstinence is reported, it will
be verified by exhaled carbon monoxide (CO) levels
using a MICRO+ Smokerlyzer, with a cut-off of < 10
ppm [42,63]. CO validation tests will be arranged during
the follow-up surveys and will be conducted by a project
officer within 3 days of the survey (with smoking status
attained again at that time), in a public location conve-
nient to the participant (eg. library) or, if not viable,
conducted as a home visit following the institutional
safety guidelines.
Secondary outcome measures
Secondary outcome measures will include: nicotine
dependence, as measured by the Fagerstrom Test of
Nicotine Dependence (FTND) [54]; changes in motiva-
tion to quit smoking, as measured by the Readiness and
Motivation to Quit Smoking Questionnaire [64]; alcohol
and other substance use, as measured by The Alcohol
Use Disorders Identification Test (AUDIT) [65]; and
mental well being, as measured by the Kessler Psycholo-
gical Distress Scale (K10) [66].
Process measures
a) All participants Details regarding participant uptake,
use and perceived effectiveness of smoking cessation
supports (provided by this trial or elsewhere) will be
collected at each of the four follow-up time points (one
week, two, four and six months post discharge) for par-
ticipants in both conditions. In addition, the follow-up
telephone interviewers will record data arising from the
outcome of each follow-up telephone survey, including
the time and date of all call attempts, call outcome (eg.
engaged, answering machine, call partially complete, call
complete or refusal), length of call, and the interviewer
who conducted the call.
b) Intervention participants For participants allocated
to the intervention condition, more detailed information
regarding uptake, use and effectiveness of the interven-
tions provided by this trial will be collected systemati-
cally at each fortnightly telephone support call,
including: intervention options elected at baseline, three
day call and initial (one week) support call; whether the
participant received their previous NRT allocation and
details of its contents; usage of NRT, including type,
dosage, and amount used per day; problems with and
perceived effectiveness of NRT; smoking cessation sup-
port group attendance and effectiveness; number, date
and effectiveness of calls received from Quitline; and
any problems experienced with the intervention options
or participation in the project. Additionally, information
regarding the process and outcome of these calls will be
recorded, including date and time of call attempts, call
outcome (eg. engaged, answering machine, call partially
complete, call complete or refusal) call duration, inter-
viewer who conducted the call, and the total number of
calls received by each participant in the intervention
support phase.
c) Cost This trial will provide a detailed evaluation of
the costs to deliver the intervention. Cost will be deter-
mined by assessing: staff time associated with initial
recruitment and follow-up support calls; NRT and other
intervention materials (including self-help brochures);
and phone and mail costs. Data for the use in calcula-
tion of costs will be collected through detailed records
of baseline interview length, support call attempts and
length, total NRT usage and associated mail costs.
Sample size and detectable difference
A total of 200 participants (approximately 100 per
group) will be recruited to the study (an estimated 70
per group at 6 month follow-up, assuming a 70% fol-
low-up rate). This number is sufficient to conduct inten-
tion to treat analyses to examine intervention
effectiveness (with 80% power and .01 level significance
tests) in terms of differences on the continuous outcome
measures (e.g., quit attempts, daily cigarette consump-
tion, nicotine dependence) of the order of 0.51 standar-
dised (effect-size) units, and 4.8 fold increases in point
prevalence abstinence (e.g., treatment group, 24% absti-
nent, vs. comparison group, 5% abstinent). A previous,
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among a mental health patient population demonstrated
statistically significant differences (20% effect size or lar-
ger) between groups on continuous outcomes including
reduction in daily cigarette consumption and nicotine
dependence levels, but not for abstinence [21]. Due to
the unique methodology and intensity of intervention
employed in the current trial, it is uncertain whether
this trial will have sufficient power to detect statistically
significant differences in abstinence between the two
conditions, however significant differences in other out-
comes are achievable. It could be argued, based on the
novel design of this trial, larger effect sizes may be
achieved, but this remains speculative.
Analysis
Data will be analysed using IBM SPSS Statistics for
Windows (version 19.0). For the key smoking-related
outcome variables, intention-to treat analyses will be
conducted, together with subgroup analyses based on
patterns of intervention uptake. For these analyses, miss-
ing data will be classified nonabstinent or as failing to
achieve reduction. Odds ratios and associated confi-
dence intervals (CI) will be reported, with the control
group as the reference point (odds ratio = 1.00). For the
continuous outcome variables (e.g., daily cigarette con-
sumption), planned comparisons between follow-up
points, from repeated-measures analyses of variance
(ANOVAs), will be used to examine group differences
in patterns of change. As a partial control for the num-
ber of statistical tests, the threshold for statistical signifi-
cance will be set at p < 0.01. Among this population,
evidence of satisfactory engagement with post-discharge
support services and progressive changes in smoking
behaviour are also considered highly desirable outcomes.
The projected sample sizes should also be sufficient to
allow an examination of correlations between selected
participant characteristics and aggregate indices of
engagement based on the various process measures.
Discussion
The research literature indicates no previously published
randomised control trials internationally to evaluate the
effectiveness of an integrated smoking cessation inter-
vention for mental health inpatients, linking inpatient
smoking care with community cessation supports. This
multimodal, integrated intervention design has been
developed to maximise the likelihood of positive smok-
ing outcomes for mental health patients, and aims to
demonstrate the feasibility, acceptability and potential
efficacy of linking inpatient smoking care to community
cessation support. The study demonstrates many
strengths. Firstly, most smoking cessation interventions
for persons with a mental illness to date have focused
on specific diagnostic groups, particularly, samples with
schizophrenia or schizoaffective disorders [33]; and have
further required patients to express a willingness or
desire to quit for participation [19]. The methodology
employed in this trial is particularly unique. No previous
studies have directly examined the effect of linking inpa-
tient smoking care to community cessation support for
mental health patients, and only very few have been
conducted in the general hospital setting [67,68]. In the
current trial, we aim to employ a ‘real life’ approach,
working within existing mental health services, systema-
tically approaching patients and determining smoking
status, and offering the project regardless of diagnosis or
motivation to quit. By offering participation to a hetero-
geneous sample of diagnostic groups and motivation
levels, this trial may demonstrate the effectiveness of
providing integrated smoking cessation treatment to
mental health inpatients in a systematic manner that
may be incorporated into existing mental health settings.
Conclusions
This manuscript provides a comprehensive description
of the methodology to be employed as part of a rando-
mised control trial to examine the feasibility, accept-
ability and potential efficacy of an integrated smoking
cessation intervention for mental health inpatients,
linking inpatient smoking care with community cessa-
tion support. The successful implementation of this
trial will provide strong evidence on which to base
judgments regarding the efficacy of this intervention
approach.
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